Trial Profile
SPARE-Scalp Preservation and Radiation Plus Alternating Electric Tumor Treatment Field (NovoTTF, Optune) for Patients With Glioblastoma: A Pilot Study
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Glioblastoma; Glioma
- Focus Adverse reactions
- Acronyms SPARE
- 03 Apr 2024 Status changed from active, no longer recruiting to completed.
- 28 Nov 2023 Planned End Date changed from 1 Sep 2021 to 26 Jan 2024.
- 28 Nov 2023 Status changed to active, no longer recruiting.